Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Arthritis Research & Therapy|March 17, 2018
Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)Peter Nash, Philip J Mease, Iain B McInnes, et al.
ACR Open Rheumatology|January 21, 2020
Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 StudyKarel Pavelka, Alan J Kivitz, Eva Dokoupilova, et al.
Arthritis and Rheumatism|December 30, 2009
Evaluation of the efficacy and safety of terguride in patients with fibromyalgia syndrome: results of a twelve-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyOliver Distler, Wolfgang Eich, Eva Dokoupilova, et al.
Arthritis Research & Therapy|December 14, 2019
FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extensionMark C Genovese, Josephine Glover, Maria Greenwald, et al.
Annals of the Rheumatic Diseases|June 26, 2012
Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled studyMark C Genovese, Patrick Durez, Hanno B Richards, et al.
The Journal of Rheumatology|January 17, 2014
One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled studyMark C Genovese, Patrick Durez, Hanno B Richards, et al.
Annals of the Rheumatic Diseases|December 4, 2020
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2Philip J Mease, Apinya Lertratanakul, Jaclyn K Anderson, et al.
Rheumatology (Oxford, England)|September 29, 2017
Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety resultsJosef S Smolen, Jung-Yoon Choe, Nenad Prodanovic, et al.
Annals of the Rheumatic Diseases|October 19, 2017
Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition studyJosef S Smolen, Jung-Yoon Choe, Nenad Prodanovic, et al.
Rheumatology and Therapy|December 5, 2020
Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2)Ana-Maria Orbai, Jordi Gratacós, Anthony Turkiewicz, et al.
Pageof 3